Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Pharm Des. 2010;16(19):2113-7.

Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.

Author information

  • 1Institute of Internal Medicine - Catholic University of Rome - l.go A. Gemelli, 8 - I-00168 Rome, Italy. g.addolorato@rm.unicatt.it

Abstract

Preclinical studies show that antagonism of the GABA(B) receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABA(B) receptor antagonist baclofen may represent an effective mediation to treat alcohol-dependent individuals. Specifically, baclofen has shown to reduce alcohol withdrawal symptoms, as well as to reduce alcohol craving and intake, and to promote alcohol abstinence. Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis. In summary, baclofen represents a safe and effective medication to treat alcohol dependence, thus holding promise as a new pharmacotherapy. However, large studies are needed to confirm the present findings.

PMID:
20482507
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk